Comparing antiviral treatments for kidney transplants from hepatitis C-infected donors to uninfected recipients
A Randomized Controlled Trial of Prophylaxis with Direct-acting Antivirals for Kidney Transplantation from Hepatitis C virus-infected donor to Uninfected Recipients (PREVENT-HCV)
This study is looking at the best way to use new medicines to prevent hepatitis C in kidney transplant patients when the donor has the virus, comparing whether it's better to give the medicine before or after the transplant, and it's for people who are getting a kidney transplant from a donor with hepatitis C.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11043309 on NIH RePORTER |
What this research studies
This research investigates the best approach to using direct-acting antivirals (DAAs) in kidney transplantation from donors infected with hepatitis C to recipients who are not infected. It aims to compare two strategies: giving DAAs as a preventive measure before transplantation versus treating the infection after the transplant. The study will involve 120 kidney transplants across six centers and will assess the safety and effectiveness of both approaches, as well as monitor potential complications. By determining the optimal treatment strategy, the research seeks to improve outcomes for kidney transplant recipients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who require a kidney transplant and are willing to receive a kidney from a hepatitis C-infected donor.
Not a fit: Patients who are already infected with hepatitis C or those who do not require a kidney transplant will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective kidney transplants from hepatitis C-infected donors, ultimately increasing the availability of donor kidneys.
How similar studies have performed: Previous research has shown early success with similar approaches in using direct-acting antivirals for hepatitis C in transplant settings, but this specific comparison has not been tested before.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Durand, Christine Marie — Johns Hopkins University
- Study coordinator: Durand, Christine Marie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.